Loading stock data…
$5.58-0.28 (-4.78%)
Aethlon Medical, Inc., a medical therapeutic company, engages in developing novel immunotherapeutic devices in the United States.
Aethlon Medical, Inc. in the Healthcare sector is trading at $5.58 with a market capitalization of $10M. Wall Street consensus targets $13.25 (2 analysts), implying a +137.5% move over the next 12 months. The stock is currently near its 52-week low of $1.41, remaining 32.7% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 22 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | — | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | — | -$1.93M↑ | -$2.06M↓ | -$1.51M↑ | -$1.79M |
| Net Income | — | -$1.88M↑ | -$2.02M↓ | -$1.49M↑ | -$1.76M |
Aethlon Medical, Inc., a medical therapeutic company, engages in developing novel immunotherapeutic devices in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device intended to address unmet needs in oncology, life-th...